Under the partnership, both firms will aim to transform the administration of injectable drugs and enhance the patient’s experience, especially for those with chronic conditions
Gerresheimer AG Headquarters at Airport City, Duesseldorf. (Credit: Gerresheimer/Wikipedia)
Germany-based Gerresheimer has partnered with Portal Instruments, a US-based developer of a next-generation needle-free drug delivery technology, to treat chronically ill patients with a new needle-free drug-delivery solution.
The German firm also acquired a minority stake in Portal Instruments through an investment.
The agreement has the option to increase the stake in the US-based firm in the future. Furthermore, Gerresheimer will have a representative on Portal’s board of directors.
Under the partnership, both firms will aim to transform the administration of injectable drugs and enhance the patient’s experience, particularly for those with chronic conditions.
Portal Instruments has developed the needle-free injector and cartridge as a part of a medication delivery platform for biologics and biosimilars.
Unlike several auto-injectors on the market, Portal’s needle-free technology can inject the same volume in less than a second, the German firm said.
As per the partnership, Gerresheimer will aid in the development of the new technology, manufacture the reusable injector, and provide pharmaceutical cartridges.
Gerresheimer CEO Dietmar Siemssen said: “Portal Instruments is developing groundbreaking technology.
“With our combined expertise in drug delivery innovations and manufacturing, we will contribute significantly to improving the patient’s quality of life as well as treatment efficiency and success.”
Siemssen added: “These results will also help to reduce costs to the healthcare system. This investment is another milestone in our strategy process formula G.
“It will add to our capabilities to offer unique and innovative solutions to our clients. Together with Portal, we will further expand our client base as well as the existing IP and product portfolio.”
Portal Instruments CEO Patrick Anquetil said: “We are delighted to be working closer with Gerresheimer, who is a well-respected industry leader in drug delivery systems.
“As solutions provider and platform integrator, Gerresheimer has deep development and manufacturing know-how as well as a strong network of global pharma and biotech customers.
“This investment will support our scaling efforts. Gerresheimer’s financial backing will also accelerate Portal’s growth plans.”